MSA Autonomic Failure Mechanism Experiment
Overview
flowchart TD
MSA["MSA"] -->|"contributes to"| synucleinopathies["synucleinopathies"]
MSA["MSA"] -->|"associated with"| NEURODEGENERATION["NEURODEGENERATION"]
MSA["MSA"] -->|"associated with"| SCHIZOPHRENIA["SCHIZOPHRENIA"]
MSA["MSA"] -->|"co discussed"| PARKINSON["PARKINSON"]
MSA["MSA"] -->|"co discussed"| PARKINSON_S["PARKINSON'S"]
alpha_synuclein["alpha_synuclein"] -->|"causes"| MSA["MSA"]
HAND["HAND"] -->|"associated with"| MSA["MSA"]
ALS["ALS"] -->|"associated with"| MSA["MSA"]
AUTISM["AUTISM"] -->|"associated with"| MSA["MSA"]
DEPRESSION["DEPRESSION"] -->|"associated with"| MSA["MSA"]
EPILEPSY["EPILEPSY"] -->|"associated with"| MSA["MSA"]
style MSA fill:#4fc3f7,stroke:#333,color:#000
bfe67bb53c3c532ef4237fa3323691ae27404769
Research Question
What drives the severe and early autonomic failure in MSA compared to PD, and can we identify protective strategies? Specifically, we aim to determine:
Which autonomic nuclei are primarily responsible for the failure?
What is the relative contribution of central vs. peripheral autonomic pathology?
Can oligodendrocyte dysfunction in autonomic regions contribute to neuronal loss?
Are there modifiable factors that could slow autonomic progression?Hypothesis
bfe67bb53c3c532ef4237fa3323691ae27404769
Experimental Design
bfe67bb53c3c532ef4237fa3323691ae27404769
Clinical Applications
...MSA Autonomic Failure Mechanism Experiment
Overview
Mermaid diagram (expand to render)
bfe67bb53c3c532ef4237fa3323691ae27404769
Research Question
What drives the severe and early autonomic failure in MSA compared to PD, and can we identify protective strategies? Specifically, we aim to determine:
Which autonomic nuclei are primarily responsible for the failure?
What is the relative contribution of central vs. peripheral autonomic pathology?
Can oligodendrocyte dysfunction in autonomic regions contribute to neuronal loss?
Are there modifiable factors that could slow autonomic progression?Hypothesis
bfe67bb53c3c532ef4237fa3323691ae27404769
Experimental Design
bfe67bb53c3c532ef4237fa3323691ae27404769
Clinical Applications
Biomarkers for autonomic dysfunction progression
Therapeutic targets for autonomic protection
Understanding of why MSA has more severe autonomic failure than PD
Differential diagnostic markers between MSA and PDMethods Detail
Human Tissue Analysis
Sample Collection
| Tissue Type | Number of Cases | Brain Regions |
|-------------|-----------------|---------------|
| MSA brainstem | 15 | LC, NTS, DMV, RVLM |
| PD brainstem | 15 | LC, NTS, DMV, RVLM |
| Control brainstem | 10 | LC, NTS, DMV, RVLM |
| MSA spinal cord | 12 | IML (T2-L2), Onuf's nucleus |
| PD spinal cord | 12 | IML (T2-L2), Onuf's nucleus |
| Control spinal cord | 8 | IML (T2-L2), Onuf's nucleus |
Histological Analysis
Nissl staining: Identify neuronal cell bodies
Immunohistochemistry:
- Tyrosine hydroxylase (TH): catecholaminergic neurons
- Alpha-synuclein: pathology detection
- Phospho-serine129 alpha-synuclein: pathologically phosphorylated
- MBP, CNP, PLP: oligodendrocyte markers
- GFAP: astrocytes
- Iba1: microglia
3.
Stereology: Optical fractionator method for neuronal counting
Image analysis: Fiji/ImageJ for quantitative assessmentiPSC Differentiation
Noradrenergic Neuron Differentiation
Neural crest induction: BMP4, FGF8, SHH
Noradrenergic specification: FGF8, BDNF, NT3
Maturation: Maturation in noradrenergic medium
Characterization: TH, DBH, PHOX2A expressionAutonomic Ganglion Neuron Differentiation
Neural crest induction: BMP4, FGF8
Autonomic specification: BMP9, NRG1
Maturation: Autonomic neuron medium
Characterization: PHOX2B, ISL1, TH expressionFunctional Assays
Electrophysiology
- Whole-cell patch clamp recording
- Action potential properties
- Membrane resistance and capacitance
- Synaptic currents
Viability Assays
- MTT reduction assay
- Live/dead staining (calcein/ethidium)
- Caspase-3 activation
- TUNEL assay
Molecular Analysis
bfe67bb53c3c532ef4237fa3323691ae27404769
Scoring
| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Mechanistic Impact | 9 | Addresses key distinguishing feature of MSA |
| Cure Proximity | 7 | May identify neuroprotective strategies |
| Feasibility | 8 | Postmortem tissue available, iPSC models exist |
| Cost Efficiency | 8 | Clear endpoints, focused study |
| Timeline | 7 | 18-30 months to meaningful results |
| Cross-Disease Value | 8 | Informs PD, DLB autonomic dysfunction |
| Biomarker Enablement | 9 | May identify autonomic progression biomarkers |
| Combinability | 7 | Complements MSA autonomic studies |
| De-risking Value | 7 | Reduces risk for autonomic-targeted therapies |
| Novelty | 8 | MSA-specific autonomic question |
Total Score: 78
Budget Estimate
| Category | Cost |
|----------|------|
| Personnel (2 FTE, 2.5 years) | $400,000 |
| Postmortem tissue acquisition | $80,000 |
| iPSC differentiation | $60,000 |
| Histology and imaging | $40,000 |
| Electrophysiology | $30,000 |
| Sequencing/omics | $50,000 |
| Contingency (20%) | $132,000 |
| Total | $792,000 |
Risk Assessment and Mitigation
Technical Risks
| Risk | Likelihood | Mitigation |
|------|------------|------------|
| Limited tissue availability | Medium | Multiple tissue banks, international collaboration |
| iPSC differentiation variability | Medium | Clone selection, quality control |
| Postmortem interval variability | Medium | Match cases by PMI, age, sex |
| Antibody specificity | Low | Use multiple antibodies, validate with knockout |
Biological Risks
| Risk | Likelihood | Mitigation |
|------|------------|------------|
| Disease heterogeneity | Medium | Use well-characterized cases, stratified analysis |
| Age-related changes | Low | Age-matched controls |
| Medication effects | Low | Document medication history, exclude recent changes |
Timeline
Year 1: Foundation
- Months 1-3: Tissue acquisition, IRB approval
- Months 4-6: Histological optimization, iPSC characterization
- Months 7-12: Phase 1 - Mapping studies
Year 2: Mechanistic Studies
- Months 13-18: Phase 2 - Oligodendrocyte interaction studies
- Months 19-24: Phase 3 - Functional validation
Year 3: Translation
- Months 25-30: Target identification, therapeutic screening
- Months 31-36: Biomarker validation, manuscript preparation
Ethical Considerations
Human Tissue
- IRB approval for use of postmortem tissue
- Appropriate consent for research use
- Compliance with NeuroBioBank guidelines
iPSC Studies
- Informed consent for cell line derivation
- Appropriate iPSC line characterization
- Regular mycoplasma testing
- Authentication of cell lines
Data Management
Primary Data
- Raw histological images stored on secure server
- Electrophysiology data in standard formats
- Sequencing data in GEO/SRA
Analysis Pipeline
- Automated image analysis with human QC
- Standardized statistical analysis plan
- Reproducible workflow documentation
Limitations
Postmortem tissue represents end-stage disease: May miss early mechanisms
iPSC models lack aging: May not fully recapitulate age-related pathology
Cellular models lack complexity: Missing glia-neuron interactions in vivo
Limited ethnic diversity: Mostly Caucasian casesFuture Directions
Early biomarker identification: Test findings in living patients
Therapeutic development: Screen for neuroprotective compounds
Disease modification: Test interventions in animal models
Personalized medicine: Patient-specific iPSC modelsbfe67bb53c3c532ef4237fa3323691ae27404769
- [Multiple System Atrophy](/diseases/multiple-system-atrophy)
- [MSA Neurotransmitter Dysfunction](/mechanisms/msa-neurotransmitter-dysfunction)
- [Autonomic Dysfunction in Atypical Parkinsonism](/mechanisms/parkinsons-autonomic-dysfunction)
- [Parkinson's Disease Autonomic Dysfunction](/mechanisms/parkinsons-autonomic-dysfunction)
- [Central Autonomic Network](/circuits/central-autonomic-network)
- [Locus Coeruleus Degeneration](/mechanisms/locus-coeruleus-degeneration)
- [Alpha-Synuclein Oligodendropathy](/mechanisms/alpha-synuclein-oligodendropathy)
Pathway Diagram
The following diagram shows the key molecular relationships involving msa-autonomic-failure-mechanism discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)